Mathijs C. M. Bunck

机构：Eli Lilly (United States) · ORCID：0000-0002-2862-6705

发表论文 83 篇 · 总被引 12226 次 · h-index 30

代表论文

• Tirzepatide Once Weekly for the Treatment of Obesity (2022 · New England Journal of Medicine · 被引 3663)
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (2024 · New England Journal of Medicine · 被引 950)
• Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (2024 · New England Journal of Medicine · 被引 944)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (2023 · JAMA · 被引 826)
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024 · New England Journal of Medicine · 被引 816)
• Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (2023 · The Lancet · 被引 758)